Eli Lilly Valuation
| LLY Stock | EUR 751.40 5.60 0.75% |
At this time, the firm appears to be overvalued. Eli Lilly shows a prevailing Real Value of €548.52 per share. The current price of the firm is €751.4. Our model computes the value of Eli Lilly from reviewing the firm fundamentals such as Shares Outstanding of 952.35 M, current valuation of 337.36 B, and Profit Margin of 0.22 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Eli stock is determined by what a typical buyer is willing to pay for full or partial control of Eli Lilly and. Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 751.4 | Real 548.52 | Hype 751.4 | Naive 795.28 |
The real value of Eli Stock, also known as its intrinsic value, is the underlying worth of Eli Lilly Company, which is reflected in its stock price. It is based on Eli Lilly's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Eli Lilly and helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors: Eli Lilly Total Value Analysis
Eli Lilly and is now estimated to have takeover price of 337.36 B with market capitalization of 275.94 B, debt of 14.74 B, and cash on hands of 2.2 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Eli Lilly fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
337.36 B | 275.94 B | 14.74 B | 2.2 B |
Eli Lilly Investor Information
About 84.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.21. Eli Lilly recorded earning per share (EPS) of 6.49. The entity last dividend was issued on the 14th of February 2023. Based on the key measurements obtained from Eli Lilly's financial statements, Eli Lilly and is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Eli Lilly Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eli Lilly has an asset utilization ratio of 57.67 percent. This implies that the Company is making €0.58 for each dollar of assets. An increasing asset utilization means that Eli Lilly and is more efficient with each dollar of assets it utilizes for everyday operations.Eli Lilly Ownership Allocation
Eli Lilly holds a total of 952.35 Million outstanding shares. The majority of Eli Lilly and outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eli Lilly to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eli Lilly. Please pay attention to any change in the institutional holdings of Eli Lilly and as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eli Lilly Profitability Analysis
The company reported the revenue of 28.54 B. Net Income was 6.24 B with profit before overhead, payroll, taxes, and interest of 21.91 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Eli Lilly's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Eli Lilly and how it compares across the competition.
About Eli Lilly Valuation
The stock valuation mechanism determines Eli Lilly's current worth on a weekly basis. Our valuation model uses a comparative analysis of Eli Lilly. We calculate exposure to Eli Lilly's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eli Lilly's related companies.Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 33815 people.
8 Steps to conduct Eli Lilly's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Eli Lilly's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Eli Lilly's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Eli Lilly's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Eli Lilly's revenue streams: Identify Eli Lilly's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Eli Lilly's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Eli Lilly's growth potential: Evaluate Eli Lilly's management, business model, and growth potential.
- Determine Eli Lilly's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Eli Lilly's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |